XLO — Xilio Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1840233 ·
Last close
$8.34
Market Cap
$54.84M
52W High
$9.25
52W Low
$6.68
ADV30
51,333
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 12,648,000 | — | -14,112,000 | -9,529,000 | 163,487,000 | 150,333,000 | 90,943,000 |
| Dec 2025 | 13,686,000 | — | -11,836,000 | 10,360,000 | 154,685,000 | 137,531,000 | 119,412,000 |
| Sep 2025 | 19,066,000 | — | -1,929,000 | -16,287,000 | 133,694,000 | 103,764,000 | 141,789,000 |
| Jun 2025 | 8,084,000 | — | -14,366,000 | -15,844,000 | 133,813,000 | 121,551,000 | 126,744,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-56,313,000
Investing CF
$-1,052,000
Financing CF
$118,650,000
CapEx
$-1,074,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.55
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-428,318,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-42,243,000
Pretax Income TTM
$-31,300,000
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$53,484,000
EBITDA
$-40,855,000
Free Cash Flow
$-23,032,876
Enterprise Value
$-93,798,120
Total Cash
$150,332,992
Total Debt
$6,638,000
Shares Out
6,575,139
Trailing EPS
$-2.28
Book Value
$7.79
ROE
-75.2%
ROA
-19.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 43,766,000 | -41,982,000 | -35,036,000 | 154,685,000 | 119,412,000 | — | -4,992,000 |
| Dec 2024 | 6,344,000 | -59,645,000 | -58,241,000 | 71,075,000 | 53,477,000 | — | -18,378,000 |
| Dec 2023 | 0 | -79,133,000 | -76,404,000 | 60,926,000 | 24,099,000 | — | -68,620,000 |
| Dec 2022 | 0 | -89,149,000 | -88,222,000 | 139,165,000 | 33,518,000 | — | -75,723,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMP | IMMUTEP Ltd | $54.57M | $0.37 | — |
| MCRB | Seres Therapeutics, Inc. | $54.42M | $5.62 | — |
| CLCS | Cell Source, Inc. | $55.72M | $0.82 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $56.53M | $1.06 | — |
| PDSB | PDS Biotechnology Corp | $56.93M | $1.02 | — |
News headlines (Yahoo Finance, 1h cache)
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates
2026-05-12 12:40 · Yahoo
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
2026-05-12 12:20 · Yahoo
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
2026-05-12 11:30 · Yahoo
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
2026-05-11 22:05 · Yahoo
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 20:30 · Yahoo
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
2026-04-17 20:01 · Yahoo
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
2026-04-16 11:30 · Yahoo
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?
2026-04-01 16:00 · Yahoo
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market
2026-03-26 13:18 · Yahoo
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
2026-03-23 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.